# US 2010/0168169 A1 · Substituted 1,3-dioxanes useful as ppar modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168169 A1
- Document ID: US20100168169A1
- Status: Published application
- Kind: A1
- Application number: 12/523,843
- Filed: 2008-01-18
- Published: 2010-07-01
- Earliest claimed: 2007-11-21
- Assignees: Evolva SA
- Inventors: Alexandra Santana Sorensen
- Web page: https://patentgrep.com/patent/US20100168169A1

## CPC

- C07D 319/06: not condensed with other rings
- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K 31/36: Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A61K 31/4433: containing a six-membered ring with oxygen as a ring hetero atom
- A61K 31/453: containing a six-membered ring with oxygen as a ring hetero atom
- A61K 31/77: of oxiranes
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 3/12: for electrolyte homeostasis
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/10: for osteoporosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/04: Immunostimulants
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 319/08: condensed with carbocyclic rings or ring systems
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 407/04: directly linked by a ring-member-to-ring-member bond
- C07D 407/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 491/10: Spiro-condensed systems
- C07D 491/113: with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Specifically useful stereoisomers of 1,3-dioxane derivatives are described and their use in the treatment of a disease or condition dependent on PPAR modulation, such as diabetes, cancer, inflammation, neurodegenerative disorders and infections as well as their use in the treatment of a disease related to TP, such as cardiovascular diseases.

## Claims

### Claim 1

A compound of formula X
wherein
A is a branched or linear carbon chain of 3 to 7 carbons, optionally containing 1 or 2 double bonds; and
W is COOH, C(O)NH—OH, NH2, SO3H, OSO3H, an aromatic group (optionally substituted with COOH, OH or NH2) or —C(O)-Rd,
wherein Rd is —NH—C1-6-alkyl (branched or linear, preferably linear), —O—C1-6-alkyl (branched or linear, preferably linear) or a saccharide; and
Ar is a phenyl, or a 5 or 6 membered heterocyclic aromatic group optionally substituted with O—Rc,
wherein Rc is C1-6-alkyl (branched or linear, preferably linear), —C(O)—C1-6-alkyl (branched or linear, preferably linear), —CH(O), a saccharide or —H; and
Rb is 2-6C alkenyl, 1-8C alkyl optionally substituted with up to three halogeno substituents, saccharide, pentafluorophenyl, aryl or aryl(1-4C)alkyl, the latter two of which may optionally have up to five substituents selected from halogeno, (1-6C)alkyl, branched or linear (1-6C)alkoxy, (1-4C)alkylenedioxy, trifluoromethyl, cyano, nitro, hydroxyl, (2-6C)alkanoyloxy, (1-6C)alkylthio, (1-6C)alkanesulphonyl, (1-6C)alkanoylamino and oxapolymethylene of 2 to 4 carbon atoms.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein A is a linear carbon chain of 5 carbons containing one cis double bond.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein W is —C(O)—Rd, wherein Rd is —OH, glycosyl or —O—CH3.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein Ar is phenyl substituted in the ortho position with —O-Rc, wherein Rc is methoxy, —C(O)—CH3, or —H.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein Rb is phenyl substituted with halogen in the ortho position.

### Claim 6

A compound of formula XI:
wherein
X is selected from the group consisting of fluoro, chloro, bromo, trifluoromethyl, substituted phenyl, cyano, methoxy, nitro, hydroxyl and —H; and
Y is selected from the group consisting of fluoro, chloro, bromo, trifluoromethyl, substituted phenyl, cyano, methoxy, nitro, hydroxyl, —C(O)-saccharide and —H; and
Rd is —NH—C1-6-alkyl (branched or linear, preferably linear), —O—C1-6-alkyl (branched or linear, preferably linear), a saccharide or —OH.

### Claim 7 (depends on 6)

The compound according to claim 6, wherein X is selected from the group consisting of halogeno.

### Claim 8 (depends on 7)

The compound according to claim 7, wherein X is chloro.

### Claim 9 (depends on 8)

The compound according to claim 8, wherein X is in the ortho position.

### Claim 10 (depends on 6)

The compound according to claim 6, wherein Y is selected from the group consisting of —OH, methoxy and —O—C(O)—CH3.

### Claim 11 (depends on 10)

The compound according to claim 10, wherein Y is in the ortho position.

### Claim 12 (depends on 6)

The compound according to claim 6, wherein Rd is —OH or —O—CH3.

### Claim 13

A compound of formula XIII:
wherein X is selected from fluoro, chloro, bromo, trifluoromethyl, optionally substituted phenyl, cyano, methoxy and nitro; and
Rc is C1-6-alkyl (branched or linear, preferably linear), —C(O)—C1-6-alkyl (branched or linear, preferably linear), —CH(O), a saccharide or —H; and
Rd is —NH—C1-6-alkyl (branched or linear, preferably linear), —O—C1-6-alkyl (branched or linear, preferably linear), glycosyl or —OH.

### Claim 14 (depends on 13)

The compound according to claim 13, wherein X is halogeno.

### Claim 15 (depends on 14)

The compound according to claim 14, wherein X is chloro.

### Claim 16 (depends on 15)

The compound according to claim 15, wherein X is in the ortho position.

### Claim 17 (depends on 13)

The compound according to claim 13, wherein Rc is methoxy, —C(O)—CH3 or —H.

### Claim 18 (depends on 17)

The compound according to claim 17, wherein —O—Rc is positioned in the ortho position.

### Claim 19 (depends on 13)

The compound according to claim 13, wherein Rd is —H or —O—CH3.

### Claim 20 (depends on 13)

The compound according to claim 13, wherein said saccharide is a glycosyl moiety.

### Claim 21 (depends on 1)

The compound according to claim 1, wherein said compound is (Z)-6-((2S,4S,5R)-2-(2-chlorophenyl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl)hex-4-enoic acid.

### Claim 22 (depends on 1)

The compound according to claim 1, wherein said compound is (Z)-6-((2S,4S,5R)-2-(2-chlorophenyl)-4-(2-methoxyphenyl)-1,3-dioxan-5-yl)hex-4-enoic acid.

### Claim 23 (depends on 1)

The compound according to claim 1, wherein said compound is (Z)-6-((2S,4S,5R)-2-(2-chlorophenyl)-4-(2-acetoxyphenyl)-1,3-dioxan-5-yl)hex-4-enoic acid.

### Claim 24 (depends on 1)

The compound according to claim 1, wherein said compound is methyl-(Z)-6-((2S,4S,5R)-2-(2-chlorophenyl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl)hex-4-enoate.

### Claim at position 25

25-39. (canceled)

### Claim 40

A method of treating or preventing a clinical condition that is a PPAR-mediated disease or condition in an individual in need thereof, comprising administering to said individual a therapeutically effective amount of the compound of formula XIII:
wherein X is selected from fluoro, chloro, bromo, trifluoromethyl, optionally substituted phenyl, cyano, methoxy and nitro; and
Rc is C1-6-alkyl (branched or linear, preferably linear), —C(O)—C1-6-alkyl (branched or linear, preferably linear), —CH(O), a saccharide or —H; and
Rd is —NH—C1-6-alkyl (branched or linear, preferably linear), —O—C1-6-alkyl (branched or linear, preferably linear), glycosyl or —OH.

### Claim 41 (depends on 40)

The method according to claim 40, wherein said clinical condition is selected from the group consisting of diabetes, cancer, inflammation, AIDS, metabolic syndrome, obesity, pre-diabetes, hypertension and dyslipidemia.

### Claim at position 28

42-49. (canceled)

### Claim 50

A method of treating or preventing a clinical condition associated with TP in an individual in need thereof, said method comprising a therapeutically effective amount of a compound of formula XIII:
wherein X is selected from fluoro, chloro, bromo, trifluoromethyl, optionally substituted phenyl, cyano, methoxy and nitro; and
Rc is C1-6-alkyl (branched or linear, preferably linear), —C(O)—C1-6-alkyl (branched or linear, preferably linear), —CH(O), a saccharide or —H; and
Rd is —NH—C1-6-alkyl (branched or linear, preferably linear), —O—C1-6-alkyl (branched or linear, preferably linear), glycosyl or —OH.

### Claim 51 (depends on 50)

The method according to claim 50, wherein said clinical condition is selected from the group consisting of myocardial infarction, thrombosis, thrombotic disorders, pulmonary hy-pertension, atherosclerosis, diabetic nephropathy, retinopathy, peripheral arterial disease, lower limb circulation, pulmonary embolism, thrombus formation, stent-triggered thrombus formation, stent-triggered hyperplasia, stent-induced restenosis, hyperplasia, septic shock, preeclampsia, asthma, rhinitis, allergic rhinitis, tumour angiogenesis and metastasis.

### Claim at position 31

52-56. (canceled)

### Claim 57

A crystalline compound of formula XIV:
wherein X is selected from fluoro, chloro, bromo, trifluoromethyl, optionally substituted phenyl, cyano, methoxy and nitro; and
Rc is C1-6-alkyl (branched or linear, preferably linear), —C(O)—C1-6-alkyl (branched or linear, preferably linear), —CH(O), a saccharide or —H;
Rd is —NH—C1-6-alkyl (branched or linear, preferably linear), —O—C1-6-alkyl (branched or linear, preferably linear), glycosyl or —OH; and
Z+ is a counterion.

### Claim 58 (depends on 57)

The crystalline compound according to claim 57, wherein X is halogen.

### Claim 59 (depends on 58)

The crystalline compound according to claim 58, wherein X is chloro.

### Claim 60 (depends on 59)

The crystalline compound according to claim 59, wherein X is in the ortho position.

### Claim 61 (depends on 57)

The crystalline compound according to claim 57, wherein Z+ is Me3CNH3+.

### Claim 62 (depends on 57)

The crystalline compound according to claim 57 wherein the salt is unsolvated having an X-ray powder diffraction pattern with at least one peak selected from the group consisting of 11+−0.2° and 20.9+−0.2° in 2-theta scale when obtained from a copper radiation source.

### Claim 63

A crystalline solvate comprising a compound of formula XIV:
wherein X is selected from fluoro, chloro, bromo, trifluoromethyl, optionally substituted phenyl, cyano, methoxy and nitro; and
Rc is C1-6-alkyl (branched or linear, preferably linear), —C(O)—C1-6-alkyl (branched or linear, preferably linear), —CH(O), a saccharide or —H;
Rd is —NH—C1-6-alkyl (branched or linear, preferably linear), —O—C1-6-alkyl (branched or linear, preferably linear), glycosyl or —OH;
Z+ is a tert-butyl amine; and
a solvent selected from group consisting of tert-butyl methyl ether, isopropyl alcohol, nitromethane, and combinations thereof.

### Claim 64 (depends on 64)

The crystalline solvate of claim 64 wherein the solvent is isopropyl alcohol.

### Claim 65 (depends on 64)

The crystalline solvate of claim 64 which comprises less than one moles of isopropyl alcohol per mole of salt.

### Claim 66 (depends on 65)

The crystalline solvate of claim 65 which is characterized by an X-ray powder diffraction pattern with a peak at 11+−0.2° and 20.9+−0.2° in 2-theta scale when obtained from a copper radiation source.

### Claim 67

The method of 40, wherein said clinical condition is a cardiovascular disorder resistant to clopidogrel and/or asprin.

### Claim 68 (depends on 67)

The method of claim 67, wherein said cardiovascular disorder is a coronary artery disease or diabetes.

### Claim 69

The method of 40, wherein said clinical condition is a nephrotic syndrome.

### Claim 70

The method of 69, wherein said nephrotic syndrome is diabetic nephropathy.

### Claim 71

A compound of the structure:
or a salt hydrate or solvate thereof.

### Claim 72 (depends on 71)

The compound of claim 71 which is of greater than 90% enantiomeric purity.

### Claim 73 (depends on 71)

The compound of claim 71 which is of greater than 95% enantiomeric purity.

### Claim 74 (depends on 71)

The compound of claim 71 which is of greater than 99% enantiomeric purity.

### Claim 75 (depends on 71)

The compound of claim 71 having characteristic absorption peaks at 11.0°±0.2°, and 20.9°±0.2° in an X-ray powder diffractogram.

### Claim 76 (depends on 75)

The compound of claim 75 which is of greater than 90% enantiomeric purity.

### Claim 77 (depends on 75)

The compound of claim 75 which is of greater than 95% enantiomeric purity.

### Claim 78 (depends on 75)

The compound of claim 75 which is of greater than 99% enantiomeric purity.

### Claim 79 (depends on 71)

A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 71 and a pharmaceutically acceptable vehicle.

### Claim 80 (depends on 79)

A method of treating or preventing a PPAR gamma responsive clinical condition, insulin resistance, diabetes, chronic inflammatory disease, arthritis, ocular inflammation, dry eye disease, skin disorder, hyperlipidemia, cancer, etc. in an patient comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 79.

### Claim 81

A crystalline compound of the structure:

### Claim 82 (depends on 81)

A solvate of the compound of claim 81, wherein the solvent is t-butyl methyl ether, isopropyl alcohol, nitromethane or combinations thereof.

### Claim 83 (depends on 82)

A solvate of the compound of claim 82, wherein the solvent is isopropyl alcohol.

### Claim 84 (depends on 82)

A solvate of the compound of claim 82 having characteristic absorption peaks at 11.0°±0.2°, and 20.9°±0.2° in an X-ray powder diffractogram.
